Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  HIV Infection

  Free Subscription


Articles published in Antivir Ther

Retrieve available abstracts of 85 articles:
HTML format
Text format



Single Articles


    February 2018
  1. BENGTSON AM, Pence BW, Eaton EF, Edwards JK, et al
    Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.
    Antivir Ther. 2018 Feb 9. doi: 10.3851/IMP3223.
    PubMed     Text format     Abstract available


    January 2018
  2. BIGLIANO P, Calcagno A, Lucchini A, Audagnotto S, et al
    The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment.
    Antivir Ther. 2018 Jan 26. doi: 10.3851/IMP3221.
    PubMed     Text format     Abstract available


  3. FIORENTINO M, Suzan-Monti M, Vilotitch A, Sagaon-Teyssier L, et al
    Renunciation of health care by people living with HIV in France is still associated with discrimination in health care services and social insecurity - results from the ANRS VESPA2 survey.
    Antivir Ther. 2018 Jan 23. doi: 10.3851/IMP3220.
    PubMed     Text format     Abstract available


  4. PETERS L, Mocroft A, Grint D, Moreno S, et al
    Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.
    Antivir Ther. 2018 Jan 5. doi: 10.3851/IMP3218.
    PubMed     Text format     Abstract available


    November 2017
  5. FALUTZ J
    Frailty: is thy name.....universal? Evolving challenges of managing effectively treated older people living with HIV.
    Antivir Ther. 2017 Nov 24. doi: 10.3851/IMP3211.
    PubMed     Text format     Abstract available


  6. VENUTO CS, Lim J, Messing S, Hunt PW, et al
    Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.
    Antivir Ther. 2017 Nov 24. doi: 10.3851/IMP3209.
    PubMed     Text format     Abstract available


  7. PATEL RR, Presti R, Harrison LC, Powderly WG, et al
    Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature.
    Antivir Ther. 2017 Nov 23. doi: 10.3851/IMP3208.
    PubMed     Text format     Abstract available


    October 2017
  8. MORTIER V, Vancoillie L, Dauwe K, Staelens D, et al
    Meticulous plasma isolation is essential to avoid false low-level viraemia in Roche Cobas HIV-1 viral load assays.
    Antivir Ther. 2017 Oct 24. doi: 10.3851/IMP3203.
    PubMed     Text format     Abstract available


  9. BINDA F, Monge E, Simonetti FR, Zanchetta N, et al
    Primary HIV infection in patients with acute hepatitis B: a report of two cases.
    Antivir Ther. 2017 Oct 12. doi: 10.3851/IMP3201.
    PubMed     Text format     Abstract available


  10. HOPPE A, Giuliano M, Lugemwa A, Thompson JA, et al
    HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
    Antivir Ther. 2017 Oct 11. doi: 10.3851/IMP3200.
    PubMed     Text format     Abstract available


  11. ECKARD AR, O'Riordan MA, Rosebush JC, Lee ST, et al
    Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth.
    Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3199.
    PubMed     Text format     Abstract available


  12. JANTARABENJAKUL W, Anugulruengkitt S, Kasipong N, Thammajaruk N, et al
    Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically-suppressed HIV-1-infected adolescents.
    Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3198.
    PubMed     Text format     Abstract available


    September 2017
  13. SANTORO MM, Di Carlo D, Armenia D, Zaccarelli M, et al
    Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.
    Antivir Ther. 2017 Sep 22. doi: 10.3851/IMP3197.
    PubMed     Text format     Abstract available


  14. MARTINEZ-VEGA R, De La Mata NL, Kumarasamy N, Ly PS, et al
    Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE).
    Antivir Ther. 2017 Sep 21. doi: 10.3851/IMP3194.
    PubMed     Text format     Abstract available


  15. SHARMA A, Hoover DR, Shi Q, Holman S, et al
    Longitudinal study of falls among HIV-infected and uninfected women: the role of cognition.
    Antivir Ther. 2017 Sep 21. doi: 10.3851/IMP3195.
    PubMed     Text format     Abstract available


  16. SRINIVASA S, Lu MT, Fitch KV, Hallett TR, et al
    Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV.
    Antivir Ther. 2017 Sep 20. doi: 10.3851/IMP3193.
    PubMed     Text format     Abstract available


    August 2017
  17. GAGLIARDINI R, Bandera A, Zaccarelli M, Sterrantino G, et al
    3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.
    Antivir Ther. 2017 Aug 11. doi: 10.3851/IMP3188.
    PubMed     Text format     Abstract available


  18. SAX P, DeJesus E, Wohl D, DeMorin J, et al
    Virological outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA >/=1,000,000 copies/ml: a post hoc analysis of Phase 3 clinical trials.
    Antivir Ther. 2017 Aug 11. doi: 10.3851/IMP3187.
    PubMed     Text format    


    July 2017
  19. YEOH HL, Cheng A, Palmer C, Crowe SM, et al
    Frailty in men living with HIV: a cross-sectional comparison of three frailty instruments.
    Antivir Ther. 2017 Jul 21. doi: 10.3851/IMP3185.
    PubMed     Text format     Abstract available


    June 2017
  20. SCHULTZE A, Paredes R, Sabin C, Phillips AN, et al
    The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.
    Antivir Ther. 2017 Jun 19. doi: 10.3851/IMP3178.
    PubMed     Text format     Abstract available


    May 2017
  21. SHILAIH M, Angst DC, Marzel A, Bonhoeffer S, et al
    Antibacterial effects of antiretrovirals, potential implications for microbiome studies in HIV.
    Antivir Ther. 2017 May 12. doi: 10.3851/IMP3173.
    PubMed     Text format     Abstract available


    April 2017
  22. YAO AH, Moore CL, Lim PL, Molina JM, et al
    Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.
    Antivir Ther. 2017 Apr 27. doi: 10.3851/IMP3171.
    PubMed     Text format     Abstract available


  23. LUBEL J, Strasser S, Stuart KA, Dore G, et al
    Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir +/- ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
    Antivir Ther. 2017 Apr 19. doi: 10.3851/IMP3168.
    PubMed     Text format     Abstract available


  24. TROTTIER B, Lake JE, Logue K, Brinson C, et al
    Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Antivir Ther. 2017 Apr 12. doi: 10.3851/IMP3166.
    PubMed     Text format     Abstract available


  25. HANKINS CA, Koulla-Shiro S, Kilmarx P, Ferrari G, et al
    Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaounde, Cameroon.
    Antivir Ther. 2017 Apr 7. doi: 10.3851/IMP3165.
    PubMed     Text format     Abstract available


  26. VAN LUIN M, Ter Beest G, Wijnberger LE, Swanink CM, et al
    Zidovudine continuous infusion in an HIV-infected pregnant woman with a phobia of swallowing pills.
    Antivir Ther. 2017 Apr 3. doi: 10.3851/IMP3164.
    PubMed     Text format     Abstract available


    March 2017
  27. TATON A, Colson P, Dhiver C, Ruiz JM, et al
    Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patients.
    Antivir Ther. 2017 Mar 31. doi: 10.3851/IMP3163.
    PubMed     Text format    


  28. AGUILERA A, Trastoy R, Barreiro P, Costa JJ, et al
    Decline and changing profile of hepatitis delta among injection drug users in Spain.
    Antivir Ther. 2017 Mar 29. doi: 10.3851/IMP3161.
    PubMed     Text format     Abstract available


  29. AFONSO P, Auclair M, Caron-Debarle M, Capeau J, et al
    Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence.
    Antivir Ther. 2017 Mar 28. doi: 10.3851/IMP3160.
    PubMed     Text format     Abstract available


  30. ECKARD AR, Rosebush JC, O'Riordan MA, Graves CC, et al
    Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation.
    Antivir Ther. 2017 Mar 22. doi: 10.3851/IMP3157.
    PubMed     Text format     Abstract available


  31. OLIVEIRA VH, Wiechmann SL, Narciso AM, Webel AR, et al
    Muscle strength is impaired in men but not in women living with HIV taking antiretroviral therapy.
    Antivir Ther. 2017 Mar 22. doi: 10.3851/IMP3159.
    PubMed     Text format     Abstract available


  32. PETOUMENOS K, Choi JY, Hoy J, Kiertiburanakul S, et al
    CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy.
    Antivir Ther. 2017 Mar 14. doi: 10.3851/IMP3155.
    PubMed     Text format     Abstract available


  33. LALLEY-CHARECZKO L, Clark D, Zuppa AF, Moorthy G, et al
    A case study of chewed Truvada(R) for PrEP maintaining protective drug levels as measured by a novel urine tenofovir assay.
    Antivir Ther. 2017 Mar 6. doi: 10.3851/IMP3151.
    PubMed     Text format     Abstract available


  34. BHAGWAT P, Ofotokun I, McComsey GA, Brown TT, et al
    Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.
    Antivir Ther. 2017 Mar 1. doi: 10.3851/IMP3148.
    PubMed     Text format     Abstract available


    February 2017
  35. BOESECKE C, Singh GK, Scholten SH, Lutz T, et al
    Telaprevir-containing triple therapy in acute HCV coinfection: The CHAT Study.
    Antivir Ther. 2017 Feb 27. doi: 10.3851/IMP3143.
    PubMed     Text format     Abstract available


  36. BISSIO E, Barbas MG, Kademian S, Bouzas MB, et al
    Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.
    Antivir Ther. 2017 Feb 24. doi: 10.3851/IMP3147.
    PubMed     Text format     Abstract available


  37. ARENAS-PINTO A, Stohr W, Clarke A, Williams I, et al
    Evaluation of CSF virological escape in patients on long-term PI monotherapy.
    Antivir Ther. 2017 Feb 24. doi: 10.3851/IMP3146.
    PubMed     Text format     Abstract available


  38. TRAN M, Wood E, Kerr T, Patterson S, et al
    Increases in CD4+ T-cell count at antiretroviral therapy initiation among HIV-positive illicit drug users during a treatment-as-prevention initiative in Canada.
    Antivir Ther. 2017 Feb 24. doi: 10.3851/IMP3145.
    PubMed     Text format     Abstract available


  39. BEHM MO, Yee KL, Fan L, Fackler P, et al
    Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects.
    Antivir Ther. 2017 Feb 16. doi: 10.3851/IMP3142.
    PubMed     Text format     Abstract available


  40. KREUTZWISER D, Sheehan N, Dayneka N, Lemire B, et al
    Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV.
    Antivir Ther. 2017 Feb 15. doi: 10.3851/IMP3139.
    PubMed     Text format     Abstract available


  41. MOTTA I, Allice T, Romito A, Ferrara M, et al
    Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.
    Antivir Ther. 2017 Feb 15. doi: 10.3851/IMP3140.
    PubMed     Text format     Abstract available


  42. BREGIGEON S, Solas C, Faucher O, Obry-Roguet V, et al
    Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.
    Antivir Ther. 2017 Feb 14. doi: 10.3851/IMP3137.
    PubMed     Text format     Abstract available


  43. LI Y, Xie J, Wang H, Han Y, et al
    Elevated pre-treatment IL-18 level is associated with HBeAg seroconversion in HIV-HBV coinfection.
    Antivir Ther. 2017 Feb 14. doi: 10.3851/IMP3136.
    PubMed     Text format     Abstract available


  44. COPPOLA N, De Pascalis S, Messina V, Di Caprio G, et al
    ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.
    Antivir Ther. 2017 Feb 6. doi: 10.3851/IMP3134.
    PubMed     Text format     Abstract available


    January 2017
  45. SQUIQUERA L, Taxman DJ, Brendle SA, Torres R, et al
    Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase I study.
    Antivir Ther. 2017 Jan 25. doi: 10.3851/IMP3133.
    PubMed     Text format     Abstract available


  46. PORTER DP, Kulkarni R, Garner W, Miller MD, et al
    Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/ tenofovir DF or efavirenz/emtricitabine/ tenofovir DF through 96 weeks.
    Antivir Ther. 2017 Jan 16. doi: 10.3851/IMP3128.
    PubMed     Text format     Abstract available


  47. MARGOT N, Cox S, Das M, McCallister S, et al
    Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide or elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Antivir Ther. 2017 Jan 11. doi: 10.3851/IMP3125.
    PubMed     Text format     Abstract available


  48. JOTWANI V, Scherzer R, Estrella MM, Jacobson LP, et al
    Association of HIV infection with biomarkers of kidney injury and fibrosis in the Multicenter AIDS Cohort Study.
    Antivir Ther. 2017 Jan 5. doi: 10.3851/IMP3124.
    PubMed     Text format     Abstract available


  49. JANSSEN S, Huson MA, Osbak KK, Rossatanga EG, et al
    HIV infection rather than concurrent opportunistic infections drives most systemic procoagulant, vascular and damage responses - a prospective cohort study in central Africa.
    Antivir Ther. 2017 Jan 5. doi: 10.3851/IMP3100.
    PubMed     Text format     Abstract available


  50. TEERAANANCHAI S, Chaivooth S, Kerr SJ, Bhakeecheep S, et al
    Life expectancy after initiation of combination antiretroviral therapy in Thailand.
    Antivir Ther. 2017 Jan 5. doi: 10.3851/IMP3121.
    PubMed     Text format     Abstract available


  51. SIMONETTI FR, Cattaneo D, Zanchetta N, Giacomet V, et al
    Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for TDM.
    Antivir Ther. 2017 Jan 4. doi: 10.3851/IMP3122.
    PubMed     Text format     Abstract available



  52. 19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2017;22.
    PubMed     Text format    


    December 2016
  53. CATTANEO D, Minisci D, Cozzi V, Riva A, et al
    Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
    Antivir Ther. 2016 Dec 23. doi: 10.3851/IMP3119.
    PubMed     Text format     Abstract available


  54. BENOIT AC, Younger J, Beaver K, Jackson R, et al
    A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada.
    Antivir Ther. 2016 Dec 7. doi: 10.3851/IMP3114.
    PubMed     Text format     Abstract available


  55. ROCKSTROH JK, Plonski F, Bansal M, Fatkenheuer G, et al
    Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
    Antivir Ther. 2016 Dec 7. doi: 10.3851/IMP3116.
    PubMed     Text format     Abstract available


  56. THOMPSON M, Lalezari JP, Kaplan R, Pinedo Y, et al
    Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
    Antivir Ther. 2016 Dec 6. doi: 10.3851/IMP3112.
    PubMed     Text format     Abstract available


    November 2016
  57. ROCKSTROH JK, Ingiliz P, Petersen J, Peck-Radosavljevic M, et al
    Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Antivir Ther. 2016 Nov 15. doi: 10.3851/IMP3108.
    PubMed     Text format     Abstract available


  58. NAICKER N, Naidoo A, Werner L, Garrett N, et al
    Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
    Antivir Ther. 2016 Nov 4. doi: 10.3851/IMP3106.
    PubMed     Text format     Abstract available


  59. GILL VC, Lynch T, Ramazani S, Krentz HB, et al
    Reporting on the prevalence of antiretroviral drug resistance in a regional HIV population over 20 years: a word of caution.
    Antivir Ther. 2016 Nov 2. doi: 10.3851/IMP3105.
    PubMed     Text format     Abstract available


    October 2016
  60. SUDJARITRUK T, Bunupuradah T, Aurpibul L, Kosalaraksa P, et al
    Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents.
    Antivir Ther. 2016 Oct 27. doi: 10.3851/IMP3103.
    PubMed     Text format     Abstract available


  61. MATOGA MM, Hosseinipour MC, Aga E, Ribaudo HJ, et al
    Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.
    Antivir Ther. 2016 Oct 14. doi: 10.3851/IMP3101.
    PubMed     Text format     Abstract available


  62. FUNDERBURG NT, Xu D, Playford MP, Joshi AA, et al
    Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity.
    Antivir Ther. 2016 Oct 14. doi: 10.3851/IMP3091.
    PubMed     Text format     Abstract available


  63. PEREZ-MATUTE P, Pichel JG, Iniguez M, Recio-Fernandez E, et al
    Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity.
    Antivir Ther. 2016 Oct 11. doi: 10.3851/IMP3099.
    PubMed     Text format     Abstract available


  64. RANDELL P, Jackson A, Milinkovic A, Boffito M, et al
    An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers.
    Antivir Ther. 2016 Oct 6. doi: 10.3851/IMP3098.
    PubMed     Text format     Abstract available


  65. COURNIL A, Hema A, Eymard-Duvernay S, Ciaffi L, et al
    Evolution of renal function in African patients initiating second line antiretroviral treatment: findings from the 2LADY-ANRS 12169 trial.
    Antivir Ther. 2016 Oct 5. doi: 10.3851/IMP3097.
    PubMed     Text format     Abstract available


    September 2016
  66. MAUSS S, Berger F, Wehmeyer MH, Ingiliz P, et al
    Effect of antiviral therapy for HCV on lipid levels.
    Antivir Ther. 2016 Sep 29. doi: 10.3851/IMP3094.
    PubMed     Text format     Abstract available


  67. CAPETTI AF, Orofino G, Sterrantino G, Cossu MV, et al
    Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
    Antivir Ther. 2016 Sep 23. doi: 10.3851/IMP3095.
    PubMed     Text format     Abstract available


  68. KELESIDIS T, Tran TT, Brown TT, Moser C, et al
    Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
    Antivir Ther. 2016 Sep 23. doi: 10.3851/IMP3093.
    PubMed     Text format     Abstract available


  69. PARK MS, Hileman CO, Sattar A, Gilkeson R, et al
    Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults.
    Antivir Ther. 2016 Sep 20. doi: 10.3851/IMP3090.
    PubMed     Text format     Abstract available


  70. TESSON T, Blot M, Fillion A, Djerad H, et al
    Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice.
    Antivir Ther. 2016 Sep 7. doi: 10.3851/IMP3084.
    PubMed     Text format     Abstract available


  71. OLDENBUETTEL C, Wolf E, Ritter A, Noe S, et al
    Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results.
    Antivir Ther. 2016 Sep 2. doi: 10.3851/IMP3082.
    PubMed     Text format     Abstract available


  72. GIROMETTI N, Nwokolo N, McOwan A, Whitlock G, et al
    Outcomes of acutely HIV-1-infected individuals following rapid antiretroviral therapy initiation.
    Antivir Ther. 2016 Sep 2. doi: 10.3851/IMP3080.
    PubMed     Text format     Abstract available


  73. KHELOUFI F, Poizot-Martin I, Garraffo R, Tavenard A, et al
    ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).
    Antivir Ther. 2016 Sep 1. doi: 10.3851/IMP3074.
    PubMed     Text format     Abstract available


    August 2016
  74. BOYD A, Miailhes P, Lascoux-Combe C, Rougier H, et al
    Renal outcomes after up to eight years of tenofovir exposure in HIV-HBV-coinfected patients.
    Antivir Ther. 2016 Aug 24. doi: 10.3851/IMP3076.
    PubMed     Text format     Abstract available


  75. NAVARRO J, Curran A, Burgos J, Torrella A, et al
    Acute leg ischaemia in an HIV-infected patient receiving antiretroviral treatment.
    Antivir Ther. 2016 Aug 22. doi: 10.3851/IMP3075.
    PubMed     Text format     Abstract available


  76. MAROCCO R, Lichtner M, Tieghi T, Pozzetto I, et al
    Herpes virus reactivation after initiation of interferon-free antiviral agents in HIV-HCV-coinfected subjects: a new immune restoration disease?
    Antivir Ther. 2016 Aug 8. doi: 10.3851/IMP3072.
    PubMed     Text format     Abstract available


    July 2016
  77. BLANCO JR, Jarrin I, Perez-Elias MJ, Gutierrez F, et al
    Combined effect of sex and age in response to antiretroviral therapy in HIV-infected patients.
    Antivir Ther. 2016 Jul 28. doi: 10.3851/IMP3071.
    PubMed     Text format     Abstract available


  78. SHARMA A, Hoover DR, Shi Q, Holman S, et al
    Falls among middle-aged women in the Women's Interagency HIV Study.
    Antivir Ther. 2016 Jul 18. doi: 10.3851/IMP3070.
    PubMed     Text format     Abstract available


    June 2016
  79. D'ALMEIDA KW, Lert F, Spire B, Dray-Spira R, et al
    Determinants of virological response to antiretroviral therapy: socio-economic status still plays a role in the era of cART. Results from the ANRS-VESPA 2 study, France.
    Antivir Ther. 2016 Jun 29. doi: 10.3851/IMP3064.
    PubMed     Text format     Abstract available


  80. BELYHUN Y, Maier M, Liebert UG
    HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
    Antivir Ther. 2016 Jun 29. doi: 10.3851/IMP3060.
    PubMed     Text format     Abstract available


  81. ARIAS A, Aguilera A, Soriano V, Benitez-Gutierrez L, et al
    Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
    Antivir Ther. 2016 Jun 24. doi: 10.3851/IMP3061.
    PubMed     Text format     Abstract available


  82. NACCARATO M, Hall E, Wai A, Ostrowski M, et al
    A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy.
    Antivir Ther. 2016 Jun 22. doi: 10.3851/IMP3059.
    PubMed     Text format     Abstract available


  83. RIVA A, Invernizzi A, Resnati C, Micheli V, et al
    Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution?
    Antivir Ther. 2016 Jun 22. doi: 10.3851/IMP3058.
    PubMed     Text format     Abstract available


    May 2016
  84. ARCHAMPONG TN, Boyce CL, Lartey M, Sagoe KW, et al
    HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
    Antivir Ther. 2016 May 11. doi: 10.3851/IMP3055.
    PubMed     Text format     Abstract available


    January 2016

  85. 18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2016;21 Suppl 1:A1-A63.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: